|Over a week ago|
Keros Therapeutics price target raised to $45 from $35 at Piper Sandler » 05:1005/2705/27/20
Piper Sandler analyst…
Piper Sandler analyst Danielle Brill raised the firm's price target on Keros Therapeutics to $45 from $35 and reiterates an Overweight rating on the shares. The analyst believes the company's lead program KER-050 is positioned to have a "compelling" clinical profile to address defective hematopoiesis in numerous settings. Early clinical data suggests broad effects on both early- and late-stage erythropoiesis, as well as thrombopoiesis, Brill tells investors in a research note. The analyst sees "significant opportunity" for share appreciation as KER-050 advances into Phase II studies for further validation of its clinical profile.
Keros Therapeutics expects cash, cash equivalents to fund operations into 2H22 » 07:1205/2205/22/20
Keros' cash and cash…
Keros' cash and cash equivalents as of March 31, 2020 was $54.5M compared to $7M as of December 31, 2019. Total cash and cash equivalents as of March 31, 2020 did not include total net proceeds of approximately $99.8M from the Company's initial public offering completed in April 2020. Keros expects that the cash and cash equivalents it had on hand at March 31, 2020, together with the net proceeds from its initial public offering, will fund its operating expenses and capital expenditure requirements into the second half of 2022.
Keros selects KER-012 as product candidate for further development » 07:1105/2205/22/20
KER-012 for the treatment…
KER-012 for the treatment of disorders associated with bone loss and for the treatment of pulmonary arterial hypertension: Keros has selected KER-012 as a product candidate for further preclinical and clinical development.
Keros plans to report data from Phase 1 trial of KER-047 in mid-2020 » 07:1105/2205/22/20
KER-047 for the treatment…
KER-047 for the treatment of anemia arising from high hepcidin levels and for the treatment of fibrodysplasia ossificans progressiva: Keros expects to complete its Phase 1 clinical trial of KER-047 in mid-2020, and to subsequently report data from this trial in the second half of 2020, subject to any delays related to the COVID-19 pandemic.
Keros plans to report topline data of Phase 1 trial of KER-050 at EHA Congress » 07:1005/2205/22/20
KER-050 for the treatment…
KER-050 for the treatment of ineffective hematopoiesis to address cytopenias: In January 2020, Keros completed a randomized, double-blind, placebo-controlled, two-part, dose-escalation Phase 1 clinical trial of KER-050 in 48 healthy post-menopausal women. Keros plans to report the positive topline data from this trial at the virtual 25th Congress of the European Hematology Association taking place June 11-14 2020. In addition, two abstracts outlining data from preclinical studies of KER-050 in multiple animal models have been accepted for presentation at the 25th Congress of the EHA taking place from June 11 to 14, 2020. Commencement of an open-label Phase 2 clinical trial of KER-050 evaluating the treatment of cytopenias, including anemia and thrombocytopenia, in patients with very low-, low- or intermediate-risk myelodysplastic syndromes is expected in the second half of 2020, subject to any delays related to the COVID-19 pandemic.
Keros Therapeutics reports Q1 EPS ($5.11) vs. ($1.61) last year » 07:0905/2205/22/20
Reports Q1 revenue $0 vs.…
Reports Q1 revenue $0 vs. $2.5M last year. "Keros continued to make meaningful strides in the first quarter of 2020 as we continued our transition from a private company to a public company," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "In addition to our continued progress in the clinic with KER-047 and KER-050, we have strengthened our balance sheet with the successful completion of our Series C financing in March 2020 and our initial public offering in April 2020. Our team continues to execute on our development plan with the aim of meeting our milestones in 2020. We are well positioned to build on our Phase 1 clinical trials with multiple planned Phase 2 clinical trials in each of our two lead programs in patients who are underserved by current therapies."
|Over a month ago|
Fly Intel: Top five analyst initiations » 10:1005/0405/04/20
KROS, QCOM, RLMD, AGLE, NVO
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Keros Therapeutics (KROS) was initiated with a Buy at H.C. Wainwright and Jefferies, an Outperform at SVB Leerink, and an Overweight at Piper Sandler. 2. Qualcomm (QCOM) initiated with an Underweight at Wells Fargo. 3. Relmada Therapeutics (RLMD) initiated with a Buy at SunTrust. 4. Aeglea BioTherapeutics (AGLE) initiated with an Overweight at Piper Sandler. 5. Novo Nordisk (NVO) initiated with a Market Perform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Keros Therapeutics initiated with a Buy at H.C. Wainwright » 07:1605/0405/04/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Andrew Fein initiated coverage of Keros Therapeutics with a Buy rating and $50 price target. diseases. As a pioneer in developing novel TGF- beta targeted therapies, Keros is able to "rapidly translate biological insights into drug candidates," Fein tells investors in a research note. The analyst believes components of Keros' pipeline and platform remain underappreciated by the Street.
Keros Therapeutics initiated with an Outperform at SVB Leerink » 06:3805/0405/04/20
SVB Leerink analyst Tom…
SVB Leerink analyst Tom Smith initiated coverage of Keros Therapeutics with an Outperform rating and $42 price target.
Keros Therapeutics initiated with a Buy at Jefferies » 06:2805/0405/04/20
Jefferies analyst Eun…
Jefferies analyst Eun Yang initiated coverage of Keros Therapeutics with a Buy rating and $37 price target. The company's lead candidate, KER-050, could potentially treat all stages of myelodysplastic syndromes and Yang forecasts greater than $1B in KER-050 sales potential in the U.S. and EU combined if the drug succeeds in trials, the analyst tells investors.